The failure of TSP-1 analog (ABT-510) in phase II trials against metastatic cancer should not discourage the continuum of research that aims to explore the therapeutic potential of TSP-1, especially in cardiovascular diseases where its importance has emerged in recent years; on the other hand, multiple phase I studies that explore the targeting of CD47 in cancer, given its inhibitory effect on the immune response, are now under way [147–150]. This evidence concerns the gene THBS1 and cardiovascular disorder.